De-Risk Your ADC Development Process With These Stability Considerations

Antibody-drug conjugates (ADCs) are a promising type of cancer treatment that combines the targeting ability of antibodies with the drug capabilities of small molecules. These ADCs have the potential to specifically target cancer cells while minimizing damage to healthy cells. However, there are several factors that need to be considered when engineering ADCs, including their stability, efficacy, and toxicity. The stability of ADCs is influenced by the conjugation process, drug-induced chemical environment change, linker characteristics, and formulation. To optimize the stability and effectiveness of ADCs, it is important to carefully consider factors such as the conjugation approach, stability of the antibody alone, exposure of the antibody to conjugation conditions, linker length, and formulation. By addressing these considerations, ADCs have the potential to be highly effective cancer therapeutics.